By Cyber Sense Billing Team · Published · Updated
Why biologics create a separate administrative workload
Biologic and other targeted systemic therapies have changed treatment for moderate to severe psoriasis, atopic dermatitis, hidradenitis suppurativa, and other conditions. They are also among the most heavily managed drugs in any health plan. Nearly every plan requires prior authorization, many require step therapy, and approvals expire on fixed schedules. For a dermatology office, this means a stream of forms, clinical notes, appeals, and pharmacy calls that has little to do with the visit claim itself but directly affects whether patients start and stay on therapy. A clear process prevents delays that frustrate patients and clinicians alike.
Pharmacy benefit or medical benefit
The first question for any biologic is which benefit covers it. Self-administered injectables are most often covered under the pharmacy benefit and dispensed by a specialty pharmacy. Drugs administered in the office or an infusion center are generally covered under the medical benefit and billed on a claim with a HCPCS drug code and administration code. Some drugs can fall under either depending on the plan. The authorization request goes to different places in each case, often a pharmacy benefit manager for pharmacy-covered drugs and the health plan or its utilization management vendor for medically covered drugs. Identifying the correct benefit avoids submitting a request to the wrong entity.
What a complete authorization request includes
Plans publish clinical criteria for each drug. Requests commonly need the diagnosis, disease severity documented with objective measures the plan recognizes, such as body surface area or a validated severity score, prior treatments tried with dates, duration, and outcomes, any contraindications to required step therapies, relevant screening results such as tuberculosis testing where the drug label or plan requires it, and the prescribed dose and frequency. Gathering these from the chart before submitting saves weeks of back-and-forth. Template note sections that prompt clinicians to record severity scores and prior therapy history at each visit make future requests much easier.
Step therapy and exceptions
Many plans require patients to try and fail specific topical or systemic treatments, or a preferred biologic, before approving a nonpreferred drug. When a patient has already tried the required drugs, perhaps under a prior plan, document the dates and results. When a required step is clinically inappropriate, many states have step therapy exception laws that set criteria and response timelines. A request for an exception should explain the clinical reason with supporting documentation, not just state a preference.
Coordinating with specialty pharmacies and manufacturer programs
After approval, the prescription usually goes to a specialty pharmacy designated by the plan. The pharmacy may contact the office for additional information, and delays often occur when nobody owns those calls. Manufacturers also offer patient support programs and copay assistance for commercially insured patients, with eligibility rules that typically exclude government insurance. The office should keep a simple record of which pharmacy each patient uses, the support program status, and the contact for each.
Tracking renewals and changes
Initial approvals often last a limited period, and renewals require evidence of response to therapy. If the chart does not document improvement in measurable terms, the renewal may be denied even though the patient is doing well. Build a renewal calendar with reminders well before expiration, and make sure follow-up visits record the same severity measures used in the initial request. When a patient changes plans, a new authorization is almost always required, so registration staff should flag insurance changes for any patient on a biologic.
Handling denials and appeals
When an authorization is denied, read the denial letter for the specific criterion not met. Many denials are resolved by supplying missing documentation or by a peer-to-peer discussion between the dermatologist and the plan's reviewer. If the denial stands, a formal appeal should address each criterion with chart evidence. Track appeal deadlines carefully, and keep copies of every submission and response so a second-level appeal or external review can build on the record.
Frequently asked questions
What if a patient's plan changes mid-treatment?
Treat it as a new request. Confirm the new plan's preferred drugs and criteria, submit an authorization with the full treatment history, and ask about transition or continuity-of-care provisions that some plans offer for patients already stable on a therapy.
What documentation helps most with renewals?
Renewals usually depend on showing that therapy is working. Record the same objective measures used in the original request, such as body surface area or a validated severity score, at each follow-up visit, along with adherence, side effects, and the clinician's assessment of response. When the chart shows measurable improvement from baseline, renewals are typically faster and less likely to be denied.
Who should submit biologic authorizations?
Many practices assign a dedicated staff member or outsource the work. What matters is one owner who tracks each request from submission through approval, pharmacy fill, and renewal.
Does Cyber Sense handle drug prior authorizations?
Our prior authorization support covers services and procedures billed by the practice. We can discuss how drug authorization work fits into your workflow during a consultation.
Can copay cards be used with Medicare?
Manufacturer copay assistance programs generally exclude patients with Medicare or other government coverage. Check each program's terms.
Sources and further reading
Related pages
Need help with dermatology billing? See our Dermatology medical billing services.
Related articles
This article is general information, not legal or coding advice. Always check current CPT®, ICD-10-CM, CMS and payer guidance. Questions? Contact us.